February 2010
BioWorld Today;2/2/2010, Vol. 21 Issue 21, p3
This section offers news briefs on the biotechnology industry including an exclusive worldwide licensing deal signed by Abbott with Pierre Fabre SA, the execution of a license agreement by Achillion Pharmaceuticals Inc. for elvucitabine, and the research agreements signed by Asuragen Inc. with several organizations, which include the University of Pittsburgh Medical Center.


Related Articles

  • PIERRE FABRE LICENSES PHARMAGENESIS ANTI-CANCER HERBAL DRUG.  // Worldwide Biotech;May2003, Vol. 15 Issue 5, p5 

    Reports that research and development company, Pharmagenesis Inc. has signed an agreement with Pierre Fabre Medicament to license PG490-88Na, a patented derivative of a compound from a plant widely used in Chinese medicine.

  • BMS Licenses Phase III Cancer Drug.  // Chemical Market Reporter;4/26/2004, Vol. 265 Issue 17, p3 

    Reports on the move of Bristol-Myers Squibb (BMS) Co. in seeking to strengthen its oncology franchise by licensing a late-phase cancer drug from Pierre Fabre Médicament SA in Paris, France. Success of BMS in taking an exclusive license to market Javlor vinflunine; Presentation of the phase...

  • Hot product.  // Drug Store News;6/17/96, Vol. 18 Issue 9, p69 

    Reports on Azusa, California-based Pierre Fabre's strength in the concealer category due to the strong sales of its Physicians Formula concealer products for the 52 weeks ended December 1995. Market share; Category growth; Product launches focusing on color correcting skin discoloration...

  • Back to nature.  // Life Science Today;Feb2001, Vol. 2 Issue 1, p6 

    Reports on the research and development venture launched by French drugmaker Pierre Fabre which focuses on natural substances. Research body that will help Pierre on its research; Sources of the substances that will be developed by the company.

  • Pierre Fabre. WEIL, JENNIFER // WWD: Women's Wear Daily;7/22/2013, Vol. 206 Issue 13, p12 

    The article presents an obituary for Pierre Fabre, founder of founder and president of pharmaceutical and cosmetics business, Laboratoires Pierre Fabre.

  • Value drivers in licensing deals. Arnold, Katie; Coia, Anthony; Saywell, Scott; Smith, Ty; Minick, Scott; Löffler, Alicia // Nature Biotechnology;Nov2002, Vol. 20 Issue 11, p1085 

    Determines the appropriate gauge on how the value of licensing deals in commercial biotechnology is identified, enhanced and captured. Three quantitative methods used to analyze biotechnology products; Value of product deals between biotechnology and pharmaceutical companies; Impact of the type...

  • Durascreen gets new marketing approach.  // Drug Store News;11/4/96, Vol. 18 Issue 18, p43 

    Reports that Pierre Fabre Dermo-Cosmetique is embarking on an aggressive marketing and educational program for the DuraScreen sun care brand. Acquisition of the brand; Marketing strategies.

  • Pierre Fabre introduces French A-Derma line to U.S. Malbin, Peter // Drug Store News;9/8/97, Vol. 19 Issue 14, p49 

    Reports on Pierre Fabre's plan to introduce its A-Derma skin care line in the United States. Price range; Product testing conducted in October 1997.

  • Pharma: Other News To Note.  // BioWorld Today;1/18/2013, Vol. 24 Issue 13, p7 

    The article reports that Castres, France-based Laboratoires Pierre Fabre Dermatologie, a subsidiary of Laboratoires Pierre Fabre and Maruho Co. Ltd. of Osaka, Japan, has entered a licensing deal to develop and market an oral formulation of a pediatric beta-blocker in Japan.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics